Testing a new drug for breast cancer that didn't fully respond to initial treatment
Treatments studied
Part of Cancer, Skin clinical trials.
This trial tests a drug called SHR-A1811 for women with HER2-positive breast cancer that did not shrink enough after 4 cycles of standard pre-surgery treatment. The goal is to see if this drug can help improve outcomes before surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Woman between 18 and 70 years old with newly diagnosed breast cancer
- Your breast cancer is HER2-positive and early stage or locally advanced (has not spread to distant organs)
- Your cancer did not respond well to 4 cycles of pre-surgery treatment as determined by your doctor
- You are physically active enough to do light housework or office work (ECOG score 0 or 1)
- You are willing to use effective birth control during the study and for 3 months after the last dose
- You have not had other cancers in the past (except for cured skin or cervical cancer)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new drug called SHR-A1811 in patients with advanced breast cancer that has a protein called HER2. The drug may help slow or stop cancer growth in patients who haven't had too many prior treatments.
This trial tests a new drug called SHR-A1811 combined with pertuzumab given before surgery to shrink tumors in people with early or locally advanced, hormone receptor-positive and HER2-positive breast cancer. It is designed to see if this combination can help reduce tumor size better.
This trial tests SHR-A1811 given before surgery (neoadjuvant treatment) for breast cancer that is hormone-receptor positive (HR-positive) and HER2-low. It aims to shrink or control the cancer early and see how well this approach works compared with standard care.
This trial tests a new drug, SHR-A1811, for people with HER2-positive bile duct cancer that has spread or cannot be removed by surgery. It may help control the cancer if you haven't had other treatments for this stage.
This trial tests whether SHR-A1811 alone, or together with pyrotinib, given before surgery, can shrink HER2-positive breast cancer. It may help you respond better to treatment while making surgery easier.
This trial tests a new antibody-drug conjugate, SHR-A1811, against the combination of pyrotinib and capecitabine in people with HER2-positive advanced breast cancer that no longer responds to trastuzumab (Herceptin). Researchers want to see if SHR-A1811 works better than the standard treatment.
Hear when a new Early Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.